Nuwellis, Inc. (NUWE)
NASDAQ: NUWE · Real-Time Price · USD
2.400
-0.040 (-1.64%)
At close: Dec 1, 2025, 4:00 PM EST
2.360
-0.040 (-1.67%)
After-hours: Dec 1, 2025, 5:06 PM EST
Nuwellis Revenue
Nuwellis had revenue of $2.22M in the quarter ending September 30, 2025, a decrease of -6.34%. This brings the company's revenue in the last twelve months to $8.17M, down -8.93% year-over-year. In the year 2024, Nuwellis had annual revenue of $8.74M, down -1.40%.
Revenue (ttm)
$8.17M
Revenue Growth
-8.93%
P/S Ratio
0.09
Revenue / Employee
$214,947
Employees
38
Market Cap
3.98M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8.74M | -124.00K | -1.40% |
| Dec 31, 2023 | 8.86M | 321.00K | 3.76% |
| Dec 31, 2022 | 8.54M | 622.00K | 7.85% |
| Dec 31, 2021 | 7.92M | 480.00K | 6.45% |
| Dec 31, 2020 | 7.44M | 1.93M | 35.02% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
NUWE News
- 19 days ago - Nuwellis, Inc. (NUWE) Q3 2025 Earnings Call Prepared Remarks Transcript - Seeking Alpha
- 19 days ago - Nuwellis Reports Third Quarter 2025 Results and Continued Operational Momentum - GlobeNewsWire
- 21 days ago - Nuwellis Receives Notice of Allowance of a New U.S. Patent Strengthening Vivian™ Pediatric System with Advanced Clamp Safety Technology - GlobeNewsWire
- 5 weeks ago - Nuwellis, Inc. To Report Third Quarter 2025 Financial Results on November 12, 2025 - GlobeNewsWire
- 2 months ago - Nuwellis Announces 92% Survival in Children with Acute Kidney Injury (AKI), Fluid Overload or Congenital Kidney Failure Following Treatment with Aquadex® - GlobeNewsWire
- 2 months ago - Nuwellis Receives New US Patent Reinforcing Vivian™ Pediatric Device Focused on Safer, More Precise Ultrafiltration - GlobeNewsWire
- 2 months ago - Nuwellis, Inc. Participates in a Virtual Investor “What This Means” Segment - GlobeNewsWire
- 2 months ago - Nuwellis' Vivian Receives $3 Million NIH Grant to Accelerate Pediatric Platform and Strengthen Fluid-Management Portfolio - GlobeNewsWire